Clinical Trials Regulations Enforcement Provisions in the UK

Overview

This guidance explains the enforcement provisions included in the UK’s Clinical Trials Regulations, outlining how compliance is monitored and how contraventions can be addressed by the Medicines and Healthcare products Regulatory Agency (MHRA). It also clarifies the offences that may arise if clinical trial requirements are not followed.
Source: Clinical Trials Regulations enforcement provisions - GOV.UK (gov.uk)

Enforcement Approach

The MHRA employs a system of escalating compliance actions that begin with engagement during inspections and may escalate to formal regulatory actions where necessary. The focus is on achieving compliance with the Regulations through proportionate and pragmatic measures.
Source: Clinical Trials Regulations enforcement provisions - GOV.UK (gov.uk)

Infringement Notices and Offences

Under the amended Clinical Trials Regulations, the provisions against which an infringement notice or offence can be raised have been expanded. An infringement notice may be issued for breaches that also constitute an offence, enabling a proportionate response without immediately resorting to criminal prosecution.
Source: Clinical Trials Regulations enforcement provisions - GOV.UK (gov.uk)

MHRA’s Compliance Philosophy

Criminal prosecution is used only as a matter of last resort. The MHRA aims to work with sponsors, investigators and other stakeholders to resolve compliance issues through inspection findings, corrective actions, or warnings before pursuing legal action.
Source: Clinical Trials Regulations enforcement provisions - GOV.UK (gov.uk)

When Enforcement Might Occur

Enforcement may become necessary when there are serious breaches of the clinical trial conditions specified in the Regulations, such as failure to comply with safety reporting requirements, significant departures from an authorised protocol, or failure to maintain required documentation. In these cases, the MHRA may escalate from informal engagement to formal notices or ultimately legal prosecution.
(Source text; summary based on overall guidance.)

Purpose of these Provisions

The aim of the expanded enforcement provisions is to safeguard participant safety, uphold the integrity of clinical research, and ensure high standards of trial conduct. By clarifying how compliance is enforced, sponsors and investigators have clearer expectations for their regulatory responsibilities in the UK.
(Source text; summary based on overall guidance.)